Patients to Be Recruited Into ASLAN004 Expansion Cohort for Atopic Dermatitis
Deedee86 / Pixabay

Patients to Be Recruited Into ASLAN004 Expansion Cohort for Atopic Dermatitis

  In a recent press release, biopharmaceutical company ASLAN Pharmaceuticals ("ASLAN") announced that it would begin recruiting patients for an expansion cohort of a clinical trial evaluating ASLAN004 for patients…

Continue Reading Patients to Be Recruited Into ASLAN004 Expansion Cohort for Atopic Dermatitis
Inventiva Introduces Design for its Phase III Nonalcoholic Steatohepatitis Trial
source: pixabay.com

Inventiva Introduces Design for its Phase III Nonalcoholic Steatohepatitis Trial

According to a story from dernieresactus.fr, the biopharmaceutical company Inventiva has recently announced plans for its upcoming phase III clinical trial. This trial will investigate its lead candidate lanifibranor as…

Continue Reading Inventiva Introduces Design for its Phase III Nonalcoholic Steatohepatitis Trial
Is CRISPR the Answer to Treating Progeria?
source: pixabay.com

Is CRISPR the Answer to Treating Progeria?

According to BioSpace, recent research has demonstrated that CRISPR gene editing could be the answer to treating progeria, or Hutchinson-Gilford progeria syndrome. The Broad Institute and NIH have collaborated to…

Continue Reading Is CRISPR the Answer to Treating Progeria?
Experimental Treatment Could be Useful in Numerous Rare and Deadly Cancers
source: pixabay.com

Experimental Treatment Could be Useful in Numerous Rare and Deadly Cancers

While novel treatments have been rapidly emerging onto the drug scene, new treatment options for pancreatic cancer have fallen behind. But now, according to OncLive’s interview with Dr. P.A. Philip,…

Continue Reading Experimental Treatment Could be Useful in Numerous Rare and Deadly Cancers
Patients Who Received CRISPR Gene Editing for Beta Thalassemia and Sickle Cell Disease Remain Pain Free
source: pixabay.com

Patients Who Received CRISPR Gene Editing for Beta Thalassemia and Sickle Cell Disease Remain Pain Free

  The initial CRISPR treatment for sickle cell disease was administered to Victoria Gray in July 2019. Victoria, a resident of Forest, Mississippi, was born with sickle cell and has…

Continue Reading Patients Who Received CRISPR Gene Editing for Beta Thalassemia and Sickle Cell Disease Remain Pain Free
Infusion of Yescarta Resulted in 44 Percent 4-year Overall Survival Rate in Large B-cell Lymphoma
source: pixabay.com

Infusion of Yescarta Resulted in 44 Percent 4-year Overall Survival Rate in Large B-cell Lymphoma

  A recent announcement by Gilead Company citing data from Kite Pharma, one of its premier companies, set out remarkable results from Kite’s Zuma-1 clinical trial. The findings confirmed that…

Continue Reading Infusion of Yescarta Resulted in 44 Percent 4-year Overall Survival Rate in Large B-cell Lymphoma
Emmaus Life Sciences Makes Drug For Sickle Cell Disease Free For Those That Can’t Pay
source: pixabay.com

Emmaus Life Sciences Makes Drug For Sickle Cell Disease Free For Those That Can’t Pay

As reported in PR NewsWire;  in an effort to help the entirety of the sickle cell disease community, Emmaus Life Sciences, Inc has announced a program that will provide their…

Continue Reading Emmaus Life Sciences Makes Drug For Sickle Cell Disease Free For Those That Can’t Pay
Report from the Neurological Alliance Calls for Improvements for Rare Neurological Disease Patients
kreatikar / Pixabay

Report from the Neurological Alliance Calls for Improvements for Rare Neurological Disease Patients

The Neurological Alliance has released a report that details the experiences that rare, neurological disease patients in the UK share and calls for improvements for these people. Experts in the…

Continue Reading Report from the Neurological Alliance Calls for Improvements for Rare Neurological Disease Patients
Impressive Results for Cilta-Cel to Treat Patients With Relapsed/Refractory Multiple Myeloma
qimono / Pixabay

Impressive Results for Cilta-Cel to Treat Patients With Relapsed/Refractory Multiple Myeloma

According to a recent report in Cancer Network, the results from CARTITUDE-1 were well received. CARTITUDE-1 is a phase 1b/2 clinical trial of the CAR T-cell treatment, Cilta-Cel, for the…

Continue Reading Impressive Results for Cilta-Cel to Treat Patients With Relapsed/Refractory Multiple Myeloma
Health Canada Approves Hyrimoz for Ankylosing Spondylitis
stevepb / Pixabay

Health Canada Approves Hyrimoz for Ankylosing Spondylitis

According to GlobeNewswire, Health Canada has approved of a biosimilar, Hyrimoz, to treat ankylosing spondylitis and eight other rare conditions. Sandoz Canada is excited about this approval, as it expands…

Continue Reading Health Canada Approves Hyrimoz for Ankylosing Spondylitis